所有图片(1)

文件

47674

FFmoc-N-三苯甲基-L-谷氨酰胺

Name: FFmoc-N-三苯甲基-L-谷氨酰胺
Brand: ALDRICH

≥98.0% (HPLC), for peptide synthesis

别名:

N_α-Fmoc-N_δ-三苯甲基-L-谷氨酰胺

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₃₉H₃₄N₂O₅

CAS号:

132327-80-1

分子量:

610.70

Beilstein:

4343953

MDL编号:

MFCD00077056

UNSPSC代码:

12352209

eCl@ss:

32160406

PubChem化学物质编号:

57651077

NACRES:

NA.26

product name

FFmoc-N-三苯甲基-L-谷氨酰胺, ≥98.0% (HPLC)

质量水平

100

检测方案

≥98.0% (HPLC)

形式

powder

旋光性

[α]/D -14.0±1.5°, c = 1% in DMF

反应适用性

reaction type: Fmoc solid-phase peptide synthesis

应用

peptide synthesis

官能团

Fmoc

储存温度

2-8°C

SMILES字符串

OC(=O)[C@H](CCC(=O)NC(c1ccccc1)(c2ccccc2)c3ccccc3)NC(=O)OCC4c5ccccc5-c6ccccc46

InChI

1S/C39H34N2O5/c42-36(41-39(27-14-4-1-5-15-27,28-16-6-2-7-17-28)29-18-8-3-9-19-29)25-24-35(37(43)44)40-38(45)46-26-34-32-22-12-10-20-30(32)31-21-11-13-23-33(31)34/h1-23,34-35H,24-26H2,(H,40,45)(H,41,42)(H,43,44)/t35-/m0/s1

InChI key

WDGICUODAOGOMO-DHUJRADRSA-N

正在寻找类似产品? 访问产品对比指南

一般描述

Fmoc-Gln(Trt)-OH 也称 Nα-Fmoc-Nδ-三苯甲基-L-谷氨酰胺，它是 Fmoc 保护的氨基酸衍生物，可用作合成肽的试剂。由于谷氨酰胺受到三苯甲基保护，因此可以防止在反应中出现不需要的取代产物。

应用

Fmoc-Gln(Trt)-OH可用作Fmoc 固相肽合成的原料，用于合成fellutamide B 和 fellutamide B的N-辛酰基类似物。

WGK

WGK 1

个人防护装备

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Neurotrophic peptide aldehydes: Solid phase synthesis of fellutamide B and a simplified analog

JS Schneekloth

Bioorganic & Medicinal Chemistry Letters, 16, 3855-3858 (2006)

Protection of carboxamide functions by the trityl residue. Application to peptide synthesis

P Sieber, et.al.

Tetrahedron Letters, 32, 739-742 (1991)

Inhibition of Kallikrein-Related Peptidases 7 and 5 by Grafting Serpin Reactive-Center Loop Sequences onto Sunflower Trypsin Inhibitor-1 (SFTI-1).

Cathleen Jendrny et al.

Chembiochem : a European journal of chemical biology, 17(8), 719-726 (2015-11-18)

Serpin proteins irreversibly inhibit serine proteases, but only a small part of the serpin reactive-center loop (RCL) is responsible for the initial protein-protein interaction (PPI). To develop peptidic protease inhibitors, kallikrein-related peptidases 7 (KLK7) and 5 (KLK5) were chosen. Firstly

A Self-Delivery Chimeric Peptide for Photodynamic Therapy Amplified Immunotherapy.

Hong Cheng et al.

Macromolecular bioscience, 19(4), e1800410-e1800410 (2018-12-24)

In this paper, a self-delivery chimeric peptide PpIX-PEG8 -KVPRNQDWL is designed for photodynamic therapy (PDT) amplified immunotherapy against malignant melanoma. After self-assembly into nanoparticles (designated as PPMA), this self-delivery system shows high drug loading rate, good dispersion, and stability as

Inhibition of Tau Protein Aggregation by Rhodanine-based Compounds Solubilized Via Specific Formulation Additives to Improve Bioavailability and Cell Viability.

Marcus Pickhardt et al.

Current Alzheimer research, 14(7), 742-752 (2017-02-06)

Anti-aggregation drugs play an important role in therapeutic approaches for Alzheimer's disease. We have previously developed a number of compounds that are able to inhibit the pathological aggregation of Tau protein. One common obstacle to application is the limited penetration

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件